Page last updated: 2024-08-23

bucindolol and Heart Failure

bucindolol has been researched along with Heart Failure in 72 studies

Research

Studies (72)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (2.78)	18.7374
1990's	17 (23.61)	18.2507
2000's	32 (44.44)	29.6817
2010's	19 (26.39)	24.3611
2020's	2 (2.78)	2.80

Authors

Authors	Studies
Abraham, I; Alkhatib, N; Erstad, B; Gharaibeh, M; Karnes, J; Klimecki, W; Lee, CS; Ramos, K; Slack, M; Sweitzer, NK	1
Abraham, WT; Aleong, R; Anand, IS; Bristow, MR; Camm, AJ; Carroll, IA; Connolly, SJ; Dufton, C; Healey, JS; Khaykin, Y; Krueger, SK; Marshall, D; Piccini, JP; Rienstra, M; Sauer, WH; van Veldhuisen, DJ; White, M; Wilton, SB; Ziegler, PD	1
Claggett, B; Jhund, PS; Køber, L; McMurray, JJV; Mogensen, UM; Rogers, JK; Shen, L	1
Parikh, KS; Piccini, JP	1
Abraham, WT; Al-Khalidi, HR; Aleong, RG; Anand, IS; Bristow, MR; Clark, RL; Connolly, SJ; Davis, GW; Dignacco, P; Dufton, C; Emery, LL; Healey, JS; Marshall, DA; Piccini, JP; Sauer, WH; Steinberg, BA; van Veldhuisen, DJ; White, M; Wilton, SB	1
Abraham, WT; Adams, KF; Blain-Nelson, P; Bristow, MR; Davis, G; Felker, GM; Fiuzat, M; Liggett, SB; Neely, M; O'Connor, CM; Parikh, KS; Whellan, DJ	1
Abraham, WT; Aleong, R; Anand, IS; Ayala-Paredes, F; Bristow, MR; Carroll, IA; Connolly, SJ; Davis, G; Dufton, C; Emery, LL; Healey, JS; Ilkhanoff, L; Kao, DP; Khaykin, Y; Krueger, SK; Marshall, D; Merkely, B; Miloradović, V; Piccini, JP; Rienstra, M; Sauer, WH; van Veldhuisen, DJ; White, M; Wilton, SB; Wranicz, JK; Ziegler, PD	1
Metra, M; Shah, P	1
Lymperopoulos, A; Negussie, S; Walklett, K	1
Abraham, WT; Aleong, RG; Anand, IS; Bristow, MR; Davis, G; Fiuzat, M; Liggett, SB; Murphy, GA; O'Connor, CM; Port, JD; Sauer, WH	1
Aleong, RG; Bristow, MR; Davis, G; Sauer, WH	1
Black-Maier, E; Piccini, JP; Steinberg, BA	1
Brunelli, C; Ferrero, S; Meliota, G; Rosa, GM	1
Bristow, MR; Cockroft, J; Humphrey, K; Lavori, P; Lazzeroni, LC; Mestroni, L; Slavov, D; Taylor, MR; Zhao, L; Zhu, X	1
Adams, KF	1
Abraham, WT; Anderson, JL; Bristow, MR; Carlquist, JF; Davis, GW; Krause-Steinrauf, H; Krishnan, V; Lavori, PW; Lazzeroni, LC; Liggett, SB; Lowes, BD; Murphy, GA; Port, JD; Robertson, AD; Thaneemit-Chen, S	1
Remme, WJ	1
Fiuzat, M; O'Connor, CM	1
Francis, GS; Sarraf, M	1
Abraham, WT; Anand, IS; Bristow, MR; Carr, J; Carson, PE; Davis, G; Fiuzat, M; Gottlieb, SS; Lazzeroni, LC; Liggett, SB; Lindenfeld, J; Medway, A; Miller, AB; Murphy, GA; Nelson, P; O'Connor, CM; Plehn, JF; Port, JD; Robertson, AD; Silver, MA; Walsh, R; White, M	1
Bristow, MR; Kao, DP; Lowes, BD; Robertson, AD; Wagner, BD	1
Aleong, R; Anand, IS; Bristow, MR; Carson, PE; Davis, G; Fiuzat, M; Gottlieb, SS; Kao, DP; Lindenfeld, J; Miller, AB; Murphy, GA; O'Connor, CM; Plehn, JF; Sauer, W; Silver, MA; White, M	1
Aleong, RG; Bristow, MR; Liggett, SB; Robertson, AD; Sauer, WH	1
Ball, S; Berning, J; Brendorp, B; Carlsen, J; Eberle, S; Hall, A; Hampton, J; Jensen, G; Køber, L; Ottesen, M; Torp-Pedersen, C; Zilles, P	1
Cherubini, A; Di Lenarda, A; Perkan, A; Salvatore, L; Sinagra, G	1
Böhm, M; Dabew, E; Engelhardt, S; Lohse, MJ; Lorenz, K; Maack, C; Schäfers, HJ; Vlaskin, L	1
Bristow, MR; Deedwania, P; Domanski, M; Follmann, D; Ghali, JK; Gilbert, E; Haffner, S; Katz, R; Krause-Steinrauf, H; Lindenfeld, J; Lowes, BD; Martin, W; McGrew, F	1
Anderson, JL; Clemson, BS; Domanski, MJ; Goldman, S; Hager, WD; Krause-Steinrauf, H; Mann, DL; Massie, BM; McNamara, DM; Murray, DR; Oren, R; Rogers, WJ	1
Adams, K; Ghali, JK; Goldman, S; Khan, S; Krause-Steinrauf, HJ; Larsen, RL; Lindenfeld, J; Lowes, B; Peberdy, MA; Rosenberg, YD; Thaneemit-Chen, S; Yancy, C; Young, J	1
Appleton, C; DeMaria, A; Eichhorn, EJ; Frantz, R; Grayburn, PA; Greenberg, B; Krause-Steinrauf, H; Mayer, SA; Oh, J; Plehn, J; St John Sutton, M	1
Deedwania, P; Fagerberg, B; Ghali, J; Goldstein, S; Gottlieb, S; Hjalmarson, A; Kjekshus, J; Waagstein, F; Wedel, H; Wikstrand, J	1
Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A	1
Abraham, WT; Bristow, MR; Domanski, MJ; Eichhorn, EJ; Hare, JM; Hattler, B; Krause-Steinrauf, H; Krueger, S; Lavori, P; Liang, CS; Lindenfeld, J; Loeb, HS; Lowes, BD; Nuzzo, R; Olson, L; Thaneemit-Chen, S; Zelis, R	1
Anh, D; Marine, JE	1
Clark, AL; Cleland, JG; Coletta, AP; Ingle, L; Lalukota, K	1
Anand, I; Anderson, JL; Bourque, JM; Carson, P; Gottlieb, S; Krause-Steinrauf, H; O'Connor, CM; Plehn, JF; Silver, MA; White, M	1
Coats, AJ	1
Abraham, WT; Anderson, JL; Bristow, MR; Carlquist, JF; Domanski, MJ; Greene, SM; Hodne, D; Krause-Steinrauf, HJ; Lavori, PW; Lazzeroni, LC; Liggett, SB; Mialet-Perez, J; Morrison, J; Nelson, B; Port, JD; Thaneemit-Chen, S; Wagoner, LE; Weber, SA	1
Burnett, JC; Frantz, RP; Grayburn, PA; Krause-Steinrauf, H; Krishnan, V; Lowes, BD; Uyeda, L; White, M	1
Bristow, MR; Lindenfeld, J; Lowes, BD; Robertson, AD; Shakar, SF; Tate, CW; Wolfel, EE; Zolty, R	1
Deitchman, D; Snyder, RW	1
Eichhorn, EJ; Hatfield, B; Heesch, CM; Marcoux, L	1
Bristow, MR; French, WJ; Gilbert, EM; Kantrowitz, NE; Kelly, P; Leatherman, G; Marshall, G; O'Connell, JB; Orie, J; Smucker, ML	1
Eichhorn, EJ	1
Lukas, MA; Mitchell, MP; Ohlstein, EH; Ruffolo, RR; Willette, RN	1
Bristow, MR; Eichhorn, EJ; Gilbert, EM; Lowes, BD; Roden, RL	1
Aiyar, N; Disa, J; Mitchell, MP; Naselsky, DP; Ohlstein, EH; Ruffolo, RR; Stadel, JM; Storer, BL; Willette, RN; Yue, TL	1
Carson, PE	1
Witkowska, M	1
Bristow, MR	1
Böhm, M; Cremers, B; Flesch, M; Höper, A; Maack, C; Südkamp, M	1
Krum, H; Whorlow, SL	1
Chavey, WE	1
Bristow, MR; Domanski, MJ; Eichhorn, EJ; Krause-Steinrauf, H; Lavori, PW	1
Braunwald, E	1
SoRelle, R	1
Coutinho, J	1
Negut, C	1
Bosimini, E	1
Czuriga, I; Edes, I	1
Yancy, CW	1
Aranda, JM; Cintron, GB; Greenberg, BH; Heng, MK; Kosolcharoen, PK; Krause-Steinrauf, HJ; Renlund, DG; Thaneemit-Chen, S; White, M	1
Bristow, MR; Handwerger, D; Klein, J; Larrabee, P; Minobe, W; Müller-Beckmann, B; Port, JD; Roden, R; Skerl, L	1
Alvarez, L; Eichhorn, EJ; Glamann, DB; Grayburn, PA; Kim, AS; Risser, RC; Willard, JE	1
Bedotto, JB; Corbett, JR; Deitchman, D; Eichhorn, EJ; Grayburn, PA; Hatfield, BA; Malloy, CR; McGhie, AL; Willard, JE	1
Crottogini, AJ; Willshaw, P	1
Anderson, JL; Deitchman, D; Gilbert, EM; Mealey, PC; Menlove, R; O'Connell, JB; Renlund, DG; Volkman, K; Woodley, SL; Yanowitz, FG	1
Bristow, MR; Gilbert, EM; O'Connell, JB	1
Bedotto, JB; Brown, M; Deitchman, D; Eichhorn, EJ; Grayburn, PA; Hatfield, BA; Malloy, CR; Willard, JE	1
Craddock, G; Lystash, J; Pollock, SG; Smucker, ML; Tedesco, C	1
Hanson, RC; Snyder, RW; Weyl, JD	1

Reviews

20 review(s) available for bucindolol and Heart Failure

Article	Year
Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. Current heart failure reports, 2017, Volume: 14, Issue:6 Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Genotype; Heart Failure; Humans; Pharmacogenetics; Propanolamines; Receptors, Adrenergic, beta-1; Stroke Volume	2017
Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. Expert review of cardiovascular therapy, 2015, Volume: 13, Issue:6 Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Heart Failure; Humans; Pharmacogenetics; Polymorphism, Genetic; Propanolamines; Receptors, Adrenergic, beta-1	2015
Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients. Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:4 Topics: Adrenergic beta-Antagonists; Animals; Atrial Fibrillation; Heart Failure; Hospitalization; Humans; Propanolamines; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-1	2017
Beta-blockers in heart failure: how far have we progressed? Postgraduate medicine, 2002, Volume: 112, Issue:5 Suppl Un Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Heart Failure; Humans; Metoprolol; Propanolamines; Sympathetic Nervous System; Ventricular Dysfunction, Left	2002
Bucindolol: new hopes from reviewing past data. Drugs of today (Barcelona, Spain : 1998), 2011, Volume: 47, Issue:5 Topics: Adrenergic beta-Antagonists; Chronic Disease; Clinical Trials as Topic; Heart Failure; Humans; Propanolamines	2011
β-blockers in stage B: a precursor of heart failure. Heart failure clinics, 2012, Volume: 8, Issue:2 Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular System; Carvedilol; Disease Progression; Heart Failure; Heart Ventricles; Humans; Ivabradine; Propanolamines; Sympathetic Nervous System; Ventricular Dysfunction, Left	2012
[Treatment of heart failure: an update]. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2002, Volume: 3, Issue:7 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Bosentan; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Heart Failure; Heart-Assist Devices; Humans; Metoprolol; Multicenter Studies as Topic; Placebos; Propanolamines; Prospective Studies; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasodilator Agents	2002
Beta blockers as anti-arrhythmic agents. Heart failure reviews, 2004, Volume: 9, Issue:2 Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamines; Randomized Controlled Trials as Topic; United States	2004
Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD. European journal of heart failure, 2004, Volume: 6, Issue:7 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arginine; Cardiotonic Agents; Cardiovascular Agents; Crataegus; Cyclic Nucleotide Phosphodiesterases, Type 3; Enoximone; Enzyme Inhibitors; Exercise Tolerance; Heart Failure; Homozygote; Humans; Oxygen Consumption; Plant Extracts; Propanolamines; Randomized Controlled Trials as Topic; Receptors, Adrenergic, beta-1; Societies, Medical; Stroke Volume; Survival Analysis; Treatment Failure; Treatment Outcome; United States	2004
Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Drugs & aging, 2006, Volume: 23, Issue:2 Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Benzopyrans; Carbazoles; Carvedilol; Chronic Disease; Ethanolamines; Heart Failure; Humans; Nebivolol; Practice Guidelines as Topic; Propanolamines; Randomized Controlled Trials as Topic	2006
Effects of bucindolol in heart failure. The American journal of cardiology, 1993, Mar-25, Volume: 71, Issue:9 Topics: Adrenergic beta-Antagonists; Animals; Heart Failure; Hemodynamics; Humans; Propanolamines	1993
The role of third-generation beta-blocking agents in chronic heart failure. Clinical cardiology, 1998, Volume: 21, Issue:12 Suppl 1 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Vasodilator Agents	1998
Beta-blocker therapy in heart failure: pathophysiology and clinical results. Current problems in cardiology, 1999, Volume: 24, Issue:7 Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Exercise; Heart Failure; Heart Rate; Hemodynamics; Humans; Imidazoles; Male; Metoprolol; Middle Aged; Propanolamines; Propranolol; Quality of Life; Stroke Volume; Time Factors; Vasodilator Agents; Xamoterol	1999
beta-adrenergic receptor blockade in chronic heart failure. Circulation, 2000, Feb-08, Volume: 101, Issue:5 Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Heart Function Tests; Humans; Metoprolol; Propanolamines; Receptors, Adrenergic, beta; Signal Transduction	2000
Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. The American journal of cardiology, 2000, Oct-15, Volume: 86, Issue:8 Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Ethanolamines; Heart Failure; Humans; Metoprolol; Nebivolol; Propanolamines	2000
The importance of beta blockers in the treatment of heart failure. American family physician, 2000, Dec-01, Volume: 62, Issue:11 Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Metoprolol; Patient Selection; Propanolamines; Randomized Controlled Trials as Topic; Severity of Illness Index	2000
[Adrenergic beta inhibitors in heart insufficiency: which and when?]. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2001, Volume: 20 Suppl 3 Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Patient Selection; Propanolamines; Randomized Controlled Trials as Topic; Sympathetic Nervous System; Ventricular Dysfunction, Left	2001
[Role of beta-blockers in the treatment of chronic heart heart failure]. Orvosi hetilap, 2001, Sep-16, Volume: 142, Issue:37 Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinical Trials as Topic; Disease Progression; Drug Administration Schedule; Heart Failure; Humans; Metoprolol; Myocardial Contraction; Patient Selection; Propanolamines; Survival Rate; Ventricular Dysfunction, Left; Ventricular Function, Left	2001
The role of race in heart failure therapy. Current cardiology reports, 2002, Volume: 4, Issue:3 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Coronary Artery Disease; Heart Failure; Humans; Hypertension; Incidence; Prognosis; Propanolamines; Racial Groups; Randomized Controlled Trials as Topic; Risk Factors; Ventricular Dysfunction, Left	2002
Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade. Heart and vessels. Supplement, 1991, Volume: 6 Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Propanolamines	1991

Trials

22 trial(s) available for bucindolol and Heart Failure

Article	Year
Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the Circulation. Arrhythmia and electrophysiology, 2021, Volume: 14, Issue:8 Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electrocardiography; Female; Follow-Up Studies; Genotype; Heart Failure; Humans; Male; Propanolamines; Receptors, Adrenergic, beta-1; Time Factors	2021
Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. JACC. Heart failure, 2017, Volume: 5, Issue:8 Topics: Adrenergic beta-Antagonists; Double-Blind Method; Emergency Service, Hospital; Endpoint Determination; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Propanolamines; Recurrence; Sample Size; Treatment Outcome	2017
A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. American heart journal, 2018, Volume: 199 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Genetic Testing; Genotype; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Propanolamines; Prospective Studies; Receptors, Adrenergic, beta-1; Stroke Volume; Treatment Outcome	2018
Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. JACC. Heart failure, 2019, Volume: 7, Issue:7 Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electrocardiography; Female; Genotype; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Mortality; Pharmacogenetics; Pharmacogenomic Variants; Precision Medicine; Propanolamines; Proportional Hazards Models; Receptors, Adrenergic, beta-1; Stroke Volume	2019
Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. JACC. Heart failure, 2013, Volume: 1, Issue:4 Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Female; Heart Failure; Humans; Male; Middle Aged; Polymorphism, Genetic; Propanolamines; Prospective Studies; Receptors, Adrenergic, beta-1; Treatment Outcome	2013
New-onset atrial fibrillation predicts heart failure progression. The American journal of medicine, 2014, Volume: 127, Issue:10 Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Disease Progression; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Propanolamines; Proportional Hazards Models; Risk Factors; Ventricular Dysfunction, Left	2014
Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenetics and genomics, 2009, Volume: 19, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Aspartic Acid Endopeptidases; Endothelin-1; Endothelin-Converting Enzymes; Endothelins; Female; Haplotypes; Heart Failure; Humans; Linkage Disequilibrium; Male; Metalloendopeptidases; Middle Aged; Models, Genetic; Pharmacogenetics; Polymorphism, Single Nucleotide; Propanolamines; Proportional Hazards Models; Receptors, Endothelin	2009
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. European journal of heart failure, 2013, Volume: 15, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Case-Control Studies; Drug Resistance; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Single Nucleotide; Propanolamines; Proportional Hazards Models; Receptors, Adrenergic, beta-1; Retrospective Studies; Treatment Outcome	2013
Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:1 Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Chi-Square Distribution; Female; Heart Failure; Heterozygote; Homozygote; Humans; Male; Middle Aged; Polymorphism, Genetic; Propanolamines; Prospective Studies; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-1; Stroke Volume; Tachycardia, Ventricular; Treatment Outcome; Ventricular Fibrillation; Ventricular Function, Left	2013
The incomplete bucindolol evaluation in acute myocardial infarction Trial (BEAT). European journal of heart failure, 2002, Volume: 4, Issue:4 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Propanolamines; Survival Rate; Ventricular Dysfunction, Left; Ventricular Function, Left	2002
Failure of benefit and early hazard of bucindolol for Class IV heart failure. Journal of cardiac failure, 2003, Volume: 9, Issue:4 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cause of Death; Endpoint Determination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prevalence; Propanolamines; Proportional Hazards Models; Prospective Studies; Risk Assessment; Stroke Volume; Survival Analysis; Time; Time Factors; Treatment Failure	2003
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Archives of internal medicine, 2004, Jul-12, Volume: 164, Issue:13 Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatigue; Female; Follow-Up Studies; Heart Conduction System; Heart Failure; Humans; Hypotension; Male; Metoprolol; Middle Aged; Propanolamines; Risk Factors; Risk Reduction Behavior; Severity of Illness Index; Statistics as Topic; Treatment Failure; Ventricular Dysfunction, Left; Withholding Treatment	2004
Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation, 2004, Sep-14, Volume: 110, Issue:11 Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Female; Heart Failure; Hospitalization; Humans; Likelihood Functions; Male; Middle Aged; Norepinephrine; Predictive Value of Tests; Propanolamines; Stroke Volume; Survival Analysis; Sympathetic Nervous System; Treatment Outcome	2004
Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. The American journal of cardiology, 2005, Mar-01, Volume: 95, Issue:5 Topics: Adrenergic beta-Antagonists; Aged; Cause of Death; Double-Blind Method; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Propanolamines; Proportional Hazards Models; Risk Factors; Survival Analysis; Treatment Outcome	2005
Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST). Journal of cardiac failure, 2007, Volume: 13, Issue:6 Topics: Adrenergic beta-Antagonists; Aged; Atrial Natriuretic Factor; Biomarkers; Endothelin-1; Endothelins; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines; Radioimmunoassay; Stroke Volume; Survival Rate; Treatment Outcome	2007
Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. The American journal of cardiology, 1995, Jun-15, Volume: 75, Issue:17 Topics: Adrenergic beta-Antagonists; Female; Heart Failure; Humans; Male; Propanolamines; Research Design; Survival Rate	1995
Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. The American journal of cardiology, 1995, Feb-15, Volume: 75, Issue:5 Topics: Adrenergic beta-Antagonists; Adult; Double-Blind Method; Heart Failure; Hemodynamics; Humans; Male; Metoprolol; Propanolamines; Retrospective Studies; Ventricular Function, Left	1995
Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation, 1994, Volume: 89, Issue:4 Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Propanolamines; Prospective Studies; Ventricular Function, Left	1994
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. The New England journal of medicine, 2001, 05-31, Volume: 344, Issue:22 Topics: Adrenergic beta-Antagonists; Aged; Chronic Disease; Double-Blind Method; Female; Heart Failure; Heart Transplantation; Hospitalization; Humans; Male; Middle Aged; Propanolamines; Proportional Hazards Models; Severity of Illness Index; Survival Analysis	2001
Effects of bucindolol on neurohormonal activation in congestive heart failure. The American journal of cardiology, 1991, Jan-01, Volume: 67, Issue:1 Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adult; Heart; Heart Failure; Hemodynamics; Humans; Iodine Radioisotopes; Iodobenzenes; Male; Middle Aged; Norepinephrine; Propanolamines; Radionuclide Imaging; Renin; Renin-Angiotensin System; Sympathetic Nervous System	1991
Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation, 1991, Volume: 84, Issue:6 Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Cardiomyopathy, Dilated; Double-Blind Method; Exercise; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Norepinephrine; Propanolamines; Ventricular Function, Left	1991
Usefulness of bucindolol in congestive heart failure. The American journal of cardiology, 1990, Sep-01, Volume: 66, Issue:5 Topics: Adrenergic beta-Antagonists; Double-Blind Method; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Propanolamines; Randomized Controlled Trials as Topic; Vasodilator Agents	1990

Other Studies

30 other study(ies) available for bucindolol and Heart Failure

Article	Year
Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:2 Topics: Antihypertensive Agents; Carvedilol; Cost-Benefit Analysis; Decision Trees; Health Expenditures; Health Services; Heart Failure; Hospitalization; Humans; Models, Econometric; Patient Acceptance of Health Care; Polymorphism, Single Nucleotide; Propanolamines; Quality-Adjusted Life Years; Racial Groups; Receptors, Adrenergic, beta-1; Stroke Volume; Trauma Severity Indices	2021
Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circulation. Genomic and precision medicine, 2018, Volume: 11, Issue:8 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amino Acid Substitution; Carvedilol; Cause of Death; Clinical Trials as Topic; Cohort Studies; Dose-Response Relationship, Drug; Female; Genotype; Heart Failure; Humans; Male; Middle Aged; Mortality; Pharmacogenetics; Pharmacogenomic Testing; Polymorphism, Genetic; Propanolamines; Receptors, Adrenergic; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-1; Retrospective Studies	2018
GENETIC-AF: Digging Deeper Into Genotype-Phenotype and Heart Failure-Atrial Fibrillation Interactions. JACC. Heart failure, 2019, Volume: 7, Issue:7 Topics: Atrial Fibrillation; Genotype; Heart Failure; Humans; Phenotype; Propanolamines	2019
β1- and α2C-adrenergic receptor polymorphisms and the antiarrhythmic effect of bucindolol in heart failure with reduced ejection fraction. Pharmacogenomics, 2013, Volume: 14, Issue:13 Topics: Adrenergic alpha-1 Receptor Antagonists; Anti-Arrhythmia Agents; Heart Failure; Humans; Polymorphism, Genetic; Propanolamines; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-1	2013
An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circulation. Heart failure, 2010, Volume: 3, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Female; Heart Failure; Humans; Male; Norepinephrine; Polymorphism, Genetic; Propanolamines; Receptors, Adrenergic, alpha-2	2010
Which beta-blocker is most effective in heart failure? Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus; Disease Progression; Ethanolamines; Heart Failure; Humans; Lung Diseases, Obstructive; Metoprolol; Myocardial Infarction; Nebivolol; Propanolamines; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling	2010
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PloS one, 2012, Volume: 7, Issue:10 Topics: Adrenergic beta-Antagonists; Adult; Aged; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Norepinephrine; Pharmacogenetics; Polymorphism, Genetic; Propanolamines; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-1	2012
A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PloS one, 2012, Volume: 7, Issue:11 Topics: Adrenergic beta-Antagonists; Adult; Area Under Curve; Bayes Theorem; Double-Blind Method; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Models, Biological; Multivariate Analysis; Propanolamines; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left	2012
Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor. Circulation, 2003, Jul-22, Volume: 108, Issue:3 Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Atrial Function; Heart Atria; Heart Failure; Heart Rate; Humans; In Vitro Techniques; Male; Metoprolol; Mice; Mice, Transgenic; Middle Aged; Myocardial Contraction; Organ Specificity; Propanolamines; Propranolol; Receptors, Adrenergic, beta-1; Species Specificity; Xamoterol	2003
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. Journal of the American College of Cardiology, 2003, Sep-03, Volume: 42, Issue:5 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Cause of Death; Diabetes Complications; Disease Progression; Female; Heart Failure; Heart Transplantation; Hospitalization; Humans; Male; Middle Aged; Prognosis; Propanolamines; Proportional Hazards Models; Retrospective Studies; Risk Factors; Severity of Illness Index; Survival Analysis; Treatment Outcome; Ventricular Function	2003
Hormone replacement therapy is associated with improved survival in women with advanced heart failure. Journal of the American College of Cardiology, 2003, Oct-01, Volume: 42, Issue:7 Topics: Aged; Aged, 80 and over; Arizona; California; Colorado; Estrogen Replacement Therapy; Female; Heart Failure; Humans; Louisiana; Maryland; Middle Aged; North Carolina; Ohio; Postmenopause; Prognosis; Propanolamines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Systole; Texas; Ventricular Dysfunction, Left; Virginia; Women's Health	2003
Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST). Circulation, 2003, Nov-11, Volume: 108, Issue:19 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Dobutamine; Echocardiography, Stress; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Myocardial Contraction; Norepinephrine; Propanolamines; Prospective Studies; Radionuclide Imaging; Stroke Volume; Ventricular Function, Left	2003
How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Cardiac electrophysiology review, 2003, Volume: 7, Issue:3 Topics: Adrenergic beta-Antagonists; Black People; Diabetic Angiopathies; Heart Failure; Humans; Hypertension; Meta-Analysis as Topic; Metoprolol; Multicenter Studies as Topic; Myocardial Infarction; Practice Patterns, Physicians'; Propanolamines; Randomized Controlled Trials as Topic	2003
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences of the United States of America, 2006, Jul-25, Volume: 103, Issue:30 Topics: Adrenergic beta-Antagonists; Amino Acid Motifs; Amino Acid Sequence; Animals; Cricetinae; Female; Genotype; Heart Failure; Heart Ventricles; Humans; Male; Molecular Sequence Data; Pharmacogenetics; Polymorphism, Genetic; Propanolamines; Receptors, Adrenergic, beta-1; Sequence Homology, Amino Acid	2006
Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). Journal of cardiac failure, 2007, Volume: 13, Issue:9 Topics: Adrenergic beta-Antagonists; Female; Health Status Indicators; Health Surveys; Heart Failure; Humans; Male; Middle Aged; Prognosis; Propanolamines; Psychological Tests; Psychometrics; Sickness Impact Profile; Surveys and Questionnaires	2007
Beneficial effects of bucindolol in a canine model of pentobarbital-induced heart failure. Archives internationales de pharmacodynamie et de therapie, 1981, Volume: 250, Issue:1 Topics: Animals; Blood Pressure; Dogs; Female; Heart Failure; Heart Rate; Hypertension; Indoles; Male; Pentobarbital; Propanolamines; Vascular Resistance	1981
Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart. Pharmacology, 1998, Volume: 56, Issue:1 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Decerebrate State; Drug Evaluation, Preclinical; Evaluation Studies as Topic; Heart Failure; Male; Propanolamines; Rats; Rats, Sprague-Dawley; Sympathomimetics	1998
In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 289, Issue:1 Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Bisoprolol; Carbazoles; Carvedilol; Cell Membrane; Cells, Cultured; Cyclic AMP; Decerebrate State; Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Iodocyanopindolol; Ligands; Male; Myocardium; Propanolamines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Xamoterol	1999
[The role of beta-adrenergic blocking agents in treatment of heart failure]. Polskie Archiwum Medycyny Wewnetrznej, 1999, Volume: 101, Issue:1 Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamines	1999
Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. British journal of pharmacology, 2000, Volume: 130, Issue:5 Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Catecholamines; Female; Guanylyl Imidodiphosphate; Heart Failure; Humans; In Vitro Techniques; Iodocyanopindolol; Male; Metoprolol; Middle Aged; Myocardial Contraction; Propanolamines	2000
Expanding indications for beta-blockers in heart failure. The New England journal of medicine, 2001, May-31, Volume: 344, Issue:22 Topics: Adrenergic beta-Antagonists; Black People; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Severity of Illness Index; Survival Analysis	2001
Beta-blocker trials seem to be in conflict. Circulation, 2001, Jun-12, Volume: 103, Issue:23 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Contraindications; Heart Failure; Humans; Propanolamines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2001
Effects of beta-blocker therapy in severe chronic heart failure. The New England journal of medicine, 2001, Sep-27, Volume: 345, Issue:13 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Propanolamines; Spironolactone; Survival Rate	2001
[Effect of carvedilol on survival in severe chronic heart failure. A trial of the beta-blocker bucindolol in patient with advanced heart failure]. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2001, Volume: 2, Issue:8 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as Topic; Heart Failure; Humans; Propanolamines; Severity of Illness Index; Survival Rate	2001
Comparison of the beta blocker bucindolol in younger versus older patients with heart failure. The American journal of cardiology, 2002, Jun-01, Volume: 89, Issue:11 Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Middle Aged; Propanolamines; Retrospective Studies	2002
Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. The Clinical investigator, 1992, Volume: 70 Suppl 1 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Binding, Competitive; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Culture Techniques; Cyclic AMP; Heart Failure; Heart Ventricles; Humans; Iodocyanopindolol; Lymphocytes; Myocardium; Pindolol; Propanolamines; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Vasodilator Agents	1992
Are contraction and relaxation coupled in patients with and without congestive heart failure? Circulation, 1992, Volume: 85, Issue:6 Topics: Adrenergic beta-Antagonists; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cyclic AMP; Deslanoside; Heart Failure; Humans; Male; Middle Aged; Models, Cardiovascular; Models, Theoretical; Myocardial Contraction; Propanolamines; Time Factors; Ventricular Function, Left	1992
Calculating the end-systolic pressure-volume relation. Circulation, 1991, Volume: 83, Issue:3 Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Myocardial Contraction; Propanolamines; Stroke Volume	1991
Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation, 1990, Volume: 82, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Coronary Circulation; Diastole; Energy Metabolism; Heart; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial Contraction; Myocardium; Oxygen Consumption; Propanolamines	1990
Differential cardioprotective properties of the l- and d- enantiomers of bucindolol in a canine model of heart failure. Archives internationales de pharmacodynamie et de therapie, 1985, Volume: 275, Issue:1 Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Dogs; Female; Heart; Heart Failure; Male; Pentobarbital; Propanolamines; Stereoisomerism; Time Factors	1985